NCT03199066 Non-Hodgkin Lymphoma - Observational Epidemiological and Clinical Study (NiHiL)
| NCT ID | NCT03199066 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Czech Lymphoma Study Group |
| Condition | Non Hodgkin Lymphoma (NHL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 1999-01-01 |
| Primary Completion | 2020-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 1999-01-01 with a primary completion date of 2020-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Czech National Lymphoma Registry (NiHiL) was founded to monitor epidemiologic data and improve the diagnostic evaluation and quality of treatment of patients with non-Hodgkin´s lymphoma (NHL). The patients are registered into the registry in anonymized form. For each patient are available: registration form, diagnostic form, treatment form, follow- up form, and other malignancy form. Data quality in the NiHiL has been checked by audits. The data is analyzed according to NHL subtypes with endpoints: lymphoma distribution, epidemiological data, prognostic characteristic, treatment characteristics, response rate, relapse rate, mortality, PFS, OS, DFS, Lymphoma specific survival, longterm toxicity.
Eligibility Criteria
Inclusion Criteria: * lymphoma diagnosis * treated in the Czech Republic * signed informed consent Exclusion Criteria: * unsigned informed consent * age \<18 y
Contact & Investigator
Marek Trneny, prof. MD
PRINCIPAL INVESTIGATOR
Charles University General Hospital, Prague, CZ
Frequently Asked Questions
Who can join the NCT03199066 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Non Hodgkin Lymphoma (NHL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03199066 currently recruiting?
Yes, NCT03199066 is actively recruiting participants. Contact the research team at trneny@cesnet.cz for enrollment information.
Where is the NCT03199066 trial being conducted?
This trial is being conducted at Prague, Czechia.
Who is sponsoring the NCT03199066 clinical trial?
NCT03199066 is sponsored by Czech Lymphoma Study Group. The principal investigator is Marek Trneny, prof. MD at Charles University General Hospital, Prague, CZ. The trial plans to enroll 20,000 participants.